Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.52 |
| ▸ | PPARD | Q03181 | 2/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11785937 | 0.85 | TSHR (0.52) | TSHRPPARDTP53TDP1CA12 | |
| SCHEMBL246310 | 0.83 | TSHR (0.50) | TSHRPPARDTP53TDP1MAPT | |
| SCHEMBL28441688 | 0.82 | TSHR (0.44) | TSHRPPARDTP53TDP1POLB | |
| SCHEMBL9605287 | 0.81 | TSHR (0.48) | TSHRPPARDTP53TDP1CA12 | |
| SCHEMBL282439 | 0.80 | TSHR (0.52) | TSHRPPARDTP53TDP1POLB | |
| SCHEMBL8643733 | 0.79 | TSHR (0.57) | TSHRPPARDTP53TDP1MAPT | |
| Hydrochloric Acid SCHEMBL15439306 | 0.78 | TSHR (0.50) | TSHRPPARDTP53TDP1POLB | |
| SCHEMBL26927745 | 0.78 | TSHR (0.50) | TSHRPPARDTP53TDP1POLB | |
| SCHEMBL2298239 | 0.78 | TSHR (0.50) | TSHRPPARDTP53TDP1POLB | |
| SCHEMBL28021215 | 0.78 | TSHR (0.50) | TSHRPPARDTP53TDP1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9486421-B2 | Treatment of lung cells with histone deacetylase inhibitors | ERRANT GENE THERAPEUTICS, LLC (US) | 2016-11-08 | — | — | US | disclosed |
| US-8138225-B2 | Histone deacetylase inhibitors based on alpha-ketoepoxide compounds | ERRANT GENE THERAPEUTICS, LLC (US) | 2012-03-20 | — | — | US | disclosed |
| US-7902259-B2 | with zinc-binding activities; 5-phenyl-2,4,-pentadienoyl hydroxamic acid; gene expression inhibitor; anticarcinogenic, antitumor, antiprotozoa agent, viricide; hematological disorders, hemoglobinopathies, genetic related metabolic disorders, cystic fibrosis | ERRANT GENE THERAPEUTICS, LLC (US) | 2011-03-08 | — | — | US | disclosed |
| US-7858664-B2 | Histone deacetylase inhibitors | ERRANT GENE THERAPEUTICS, LLC (US) | 2010-12-28 | — | — | US | disclosed |
| US-7842727-B2 | Histone deacetylase inhibitors | ERRANT GENE THERAPEUTICS, LLC (US) | 2010-11-30 | — | — | US | disclosed |
| US-20100234455-A1 | Histone Deacetylase Inhibitors | ERRANT GENE THERAPEUTICS, LLC | 2010-09-16 | — | — | US | disclosed |
| US-20100143961-A1 | Histone deacetylase inhibitors based on alpha-ketoepoxide compounds | ERRANT GENE THERAPEUTICS, LLC | 2010-06-10 | — | — | US | disclosed |
| US-7579372-B2 | Histone deacetylase inhibitors based on alpha-ketoepoxide compounds | ERRANT GENE THERAPEUTICS, LLC (US) | 2009-08-25 | — | — | US | disclosed |
| US-20080312324-A1 | Treatment of lung cells with histone deacetylase inhibitors | ERRANT GENE THERAPEUTICS, LLC | 2008-12-18 | — | — | US | disclosed |
| US-7314953-B2 | Treatment of lung cells with histone deacetylase inhibitors | ERRANT GENE THERAPEUTICS, LLC (US) | 2008-01-01 | — | — | US | disclosed |
| US-7312247-B2 | Histone deacetylase inhibitors | ERRANT GENE THERAPEUTICS, LLC (US) | 2007-12-25 | — | — | US | disclosed |
| US-7214831-B2 | Histone deacetylase inhibitors based on alpha-chalcogenmethylcarbonyl compounds | ERRANT GENE THERAPEUTICS, LLC (US) | 2007-05-08 | — | — | US | disclosed |
| US-7193105-B2 | Histone deacetylase inhibitors based on trihalomethylcarbonyl compounds | ERRANT GENE THERAPEUTICS, LLC (US) | 2007-03-20 | — | — | US | disclosed |
| US-20070037869-A1 | Treating spinal muscular atrophy with an effective amount of carboxylic acid derivative or hydroxamic acid derivative compound; treating cancer, blood disorders, genetic related metabolic disorders; 5-phenyl-2,4-pentadienoic acid | ERRANT GENE THERAPEUTICS, LLC | 2007-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100234455-A1 | Histone Deacetylase Inhibitors | HDAC1, HDAC2, HDAC11 | TSHR 662/4885PPARD 1114/4885TP53 2067/4885 |
| US-20080312324-A1 | Treatment of lung cells with histone deacetylase inhibitors | HDAC1, HDAC2, HDAC3 | TSHR 3587/4885PPARD 964/4885TP53 4152/4885 |
| US-20070037869-A1 | Treating spinal muscular atrophy with an effective amount of carboxylic acid derivative or hydroxamic acid derivative compound; treating cancer, blood disorders, genetic related metabolic disorders; 5-phenyl-2,4-pentadienoic acid | HDAC5, HDAC1, ZNF277 | TSHR 3700/4885PPARD 207/4885TP53 2343/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.